Cullinan Therapeutics (CGEM) Revenue (2021)

Cullinan Therapeutics' (CGEM) quarterly Revenue came in at $18.9 million in Q1 2021.

Cullinan Therapeutics (CGEM) Revenue (2021) Analysis & Trends

Cullinan Therapeutics' Revenue history runs 1 years deep, the most recent figure standing at $18.9 million for Q1 2021.

  • On a quarterly basis, Revenue changed N/A year-over-year to $18.9 million in Q1 2021; TTM through Dec 2021 was $18.9 million, a N/A change from a year earlier, with the FY2021 full-year figure at $18.9 million, changed N/A from the prior year.
  • Revenue held at $18.9 million in Q1 2021 per CGEM's latest filing.
  • Across five years, Revenue topped out at $18.9 million in Q1 2021 and bottomed at $18.9 million in Q1 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 1.51 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 2.99 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 3.61 Bn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 1.30 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Cullinan Therapeutics 367.37 Mn 367.37 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2021 18.94 Mn